Head-To-Head Comparison: BioSig Technologies (BSGM) and AxoGen (AXGN)

BioSig Technologies (OTCMKTS: BSGM) and AxoGen (NASDAQ:AXGN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitability and earnings.

Earnings & Valuation

This table compares BioSig Technologies and AxoGen’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioSig Technologies N/A N/A -$12.69 million N/A N/A
AxoGen $60.43 million 28.65 -$10.44 million ($0.31) -161.61

AxoGen has higher revenue and earnings than BioSig Technologies.


This table compares BioSig Technologies and AxoGen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioSig Technologies N/A N/A -1,096.27%
AxoGen -18.83% -61.66% -21.29%

Insider & Institutional Ownership

0.0% of BioSig Technologies shares are held by institutional investors. Comparatively, 75.9% of AxoGen shares are held by institutional investors. 26.7% of BioSig Technologies shares are held by company insiders. Comparatively, 7.9% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for BioSig Technologies and AxoGen, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioSig Technologies 0 0 1 0 3.00
AxoGen 0 0 8 0 3.00

AxoGen has a consensus target price of $41.29, suggesting a potential downside of 17.59%. Given AxoGen’s higher probable upside, analysts clearly believe AxoGen is more favorable than BioSig Technologies.

Volatility & Risk

BioSig Technologies has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, AxoGen has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500.


AxoGen beats BioSig Technologies on 6 of the 10 factors compared between the two stocks.

About BioSig Technologies

BioSig Technologies, Inc., a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures. It is also developing a library of software tools that are designed to be configured to fit the needs of electrophysiologists in various settings and for arrhythmia treatments. The company was founded in 2009 and is headquartered in Los Angeles, California.

About AxoGen

AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply